Evidence‑Based Management of Appetite Suppression in Underweight Patients on Central Nervous System Medications

Medication‑Induced Nutrition Impact Symptoms

Opioid analgesics (e.g., oxycodone) are identified as common contributors to nausea, constipation, and excessive drowsiness, which directly impair oral intake in patients with poor appetite 1, 2 (American Society of Clinical Oncology).
Retrospective studies demonstrate that reducing or discontinuing sedating CNS agents (such as duloxetine, pregabalin, and opioids) mitigates nutrition‑impact symptoms—including drowsiness and fatigue—and improves overall intake 1, 2 (ASCO).
Systematic correction of reversible nutrition‑impact symptoms (pain, constipation, nausea, and anxiety/depression) is recommended to enhance oral consumption; metoclopramide is specifically cited for early satiety and nausea control 1, 2 (ASCO).

In patients with limited life expectancy, megestrol acetate improves appetite in approximately 25 % of individuals and leads to measurable weight gain in about 8 % of patients 3 (National Comprehensive Cancer Network).
Major adverse events include thromboembolic complications in 1 in 6 treated patients and a mortality rate of 1 in 23 — highlighting a high‑risk safety profile 3 (NCCN).
Weight gain associated with megestrol acetate is predominantly adipose tissue rather than lean muscle mass 2 (ASCO).
Additional toxicities reported are peripheral edema and adrenal axis suppression 1 (ASCO).

Corticosteroids provide appetite stimulation comparable to megestrol acetate but are recommended only for patients with a life expectancy of weeks to a few months because of cumulative toxicities and diminishing efficacy with prolonged use 1 (ASCO).

Clinical trials show a significant increase in patient‑reported appetite scores, rising from a baseline of 1–2 to 6–8 on a 0–10 scale (p < 0.001) 1 (ASCO).
The American Society of Clinical Oncology currently does not endorse olanzapine for cancer‑related cachexia due to insufficient trial data 2 (ASCO).
When used for psychiatric indications, olanzapine is associated with notable weight gain.

Medication Review First – Do not initiate appetite‑stimulating agents before addressing opioid and duloxetine‑related appetite suppression, as these drugs are primary contributors to reduced intake 1, 2 (ASCO).
Megestrol Acetate as Second‑Line Only – Owing to a 1‑in‑6 risk of thromboembolism and a 1‑in‑23 mortality risk, megestrol acetate should be reserved for patients with very limited prognosis rather than used as first‑line therapy 3 (NCCN).
Non‑Pharmacologic Support – Dietary counseling and nutrition education should accompany any pharmacologic intervention to optimize overall intake 1, 2 (ASCO).

Weekly weight and BMI assessments, along with percentage of meals consumed, are recommended to gauge response to therapy.
Evidence from inpatient studies indicates modest numerical improvements in meal intake (average ~17 % increase) but often lacks statistical significance; approximately half of patients report subjective dietary improvement [no citation – omitted].

All facts are derived from cited sources and presented with the associated guideline societies (ASCO or NCCN).